Molecular prognostic markers in pancreatic cancer

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 9, Issue 1, 2002, Pages 1-11

  Ghaneh, Paula ^a   Kawesha, Anthony ^a   Evans, James D ^a   Neoptolemos, John P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Molecular marker; Pancreatic cancer; Prognosis

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CYCLIN D1; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MOLECULAR MARKER; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P16; PROTEIN P21; PROTEIN P53; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; ONCOGENE K RAS; PANCREAS CANCER; PREDICTION; PROGNOSIS; WESTERN HEMISPHERE;

APOPTOSIS; CELL ADHESION MOLECULES; GENES, TUMOR SUPPRESSOR; GROWTH SUBSTANCES; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PANCREATIC NEOPLASMS; PLASMINOGEN ACTIVATORS; PROGNOSIS; RECEPTORS, GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 0036244089     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005340200000     Document Type: Article

References (99)

1. The incidence and treatment and survival in 13 560 patients with pancreatic cancer: An epidemiological study in the West Midlands
2. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units
3. Population based analysis of treatment of pancreatic cancer and Whipple resection: Department of Defense hospitals 1989-1994
4. Progress report: A randomised multicentre European study comparing adjuvant radiotherapy, 6 months chemotherapy and combination therapy versus no adjuvant treatment in resectable pancreatic cancer
5. Adjuvant radiotherapy and follow-on chemotherapy in patients with pancreatic cancer
6. Prognostic indicators for survival after resection of pancreatic adenocarcinoma
7. Prognostic factors for survival after pancreaticduodenectomy for patients with carcinoma of the pancreatic head region
8. Pancreatic cancer treatment in the United States veteran from 1987-1991-effect of tumour stage on survival
9. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy
10. TNM Classification of malignant tumours
11. Classification of pancreatic carcinoma
12. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: A new prognostic factor
13. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA19.9
14. CA 19.9 serum course and prognosis of pancreatic cancer
15. Prognostic significance of preimmunotherapy serum CA27.29 (MUC 1) mucin level after specific immunotherapy of metastatic adenocarcinoma patients
16. Homozygous deletion map at 18q21.1 in pancreatic cancer
17. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerisation in growth signalling
18. The type 1 (EGFR related) family of growth factor receptors and their ligands
19. Signal transduction by receptors with tyrosine kinase activity
20. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer
21. Overexpression of the epidermal growth factor receptor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha
22. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
23. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer
24. Amphiregulin is a potent mitogen in human pancreatic cancer cells - Correlation with patient survival
25. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
26. C-erb-B2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value
27. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis
28. The c-erbB-2 protooncogene in human pancreatic cancer
29. Overexpression of her2/neu oncogene in pancreatic cancer correlates with shortened survival
30. Elevated serum c-erbB-2 protein levels in patients with pancreatic cancer: Correlation to metastasis and shorter survival
31. WAF-1, cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma
32. Expression of the C-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1
33. The c-erbB-3 gene in human pancreatic cancer
34. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumour progression
35. erbB4, a fourth member of the epidermal growth factor family
36. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu Differentiation Factor/Heregulin isoforms
37. Betacellulin activates the epidermal growth factor receptor and erbB-4 and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta
38. c-erbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer
39. Interaction between p53 and TGF-β-1 in control of epithelial cell proliferation
40. Transforming growth factor β induces the cyclin dependent kinase inhibitor p21 through a p53 independent mechanisms
41. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival
42. Presence of two signalling TGF-beta receptors in human pancreatic cancer correlates with advanced tumour stage
43. WAF1, and TGF-β1 in human ductal adenocarcinoma of the pancreas
44. Enhanced expression of the type II transforming growth factor-beta receptor in human pancreatic cancer cells without alternation of type III receptor expression
45. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumour stage
46. Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer
47. Expression of fibroblast growth factor and its receptor in human pancreatic carcinomas
48. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer
49. Prognostic significance of molecular alterations in human pancreatic carcinoma - An immunohistological study
50. Participation of the p53 protein in the cellular response to DNA damage
51. The p53 tumour suppressor gene
52. P53 mutations in human cancers
53. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer
54. Expression of p53 in precursor lesions and adenocarcinoma of the human pancreas
55. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas
56. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer
57. P53 expression affects the efficacy of adjuvant chemotherapy after resection of invasive ductal carcinoma of the pancreas
58. Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas
59. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/cdk4
60. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:cdk4/6 complexes results in active pRb
61. INK4 requires functional retinoblastoma protein
62. Frequent somatic mutations and homozygous deletions of the MTS1 gene in pancreatic adenocarcinoma
63. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alternations in p16/MTS1 in pancreatic tumours
64. Aberrant p16 (INK4) expression related to clinical stage and prognosis in patients with pancreatic cancer
65. p21 is a universal inhibitor of cyclin kinases
66. p53 controls both the G(2)M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts
67. Molecular pathology of primary and metastatic ductal pancreatic lesions. Analyses of mutations and expression of the p53, mdm-2, and p21/WAF1-1 genes in sporadic and familial lesions
68. Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumours of the human pancreas
69. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas
70. Ki-ras oncogene activation in preinvasive pancreatic cancer
71. K-ras topographic genotyping of pancreatic adenocarcinoma
72. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant enriched polymerase chain reaction analysis and allele specific oligonucleotide hybridisation
73. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma
74. Direct binding of cyclin D to the retinoblastoma gene product pRb and pRb phosphorylation by the cyclin dependent kinase cdk4
75. Inhibitors of mammalian G1 cyclin dependent kinases
76. Genetic alterations of cyclins, cyclin-dependent kinases and cdk inhibitors in human cancer
77. A p161INK4A-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
78. Bcl-2 and other inhibitors of apoptosis: Mechanisms of action
79. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
80. Apoptosis: Regulation and oncogenesis
81. Bax but not bcl-2 influences the prognosis of human pancreatic cancer
82. Expression of bcl-xL correlates with survival in pancreatic cancer
83. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer
84. Immunohistochemical analysis of bcl-2, bax, bcl-x and mcl-1 expression in pancreatic cancers
85. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness
86. Expression of two angiogenic factors, vascular endothelial growth factor and platelet derived endothelial cell growth factor in human pancreatic cancer and its relationship to angiogenesis
87. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma
88. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma
89. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities
90. Indentification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor
91. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma
92. Prognostic significance of angiogenesis in pancreatic cancer
93. Tumour associated proteases
94. Independent regulation of matrix metalloproteinase and plasminogen activators in human fibrosarcoma cells
95. Involvement of PA/plasmin system in the processing of pro-MMP9 and in the second step of pro-MMP2 activation
96. Cadherin cell adhesion receptor as a morphogenic regulator
97. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease
98. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma
99. Involvement of MMP2 activity in invasion and metastases of pancreatic cancer